**Name of journal:** ***World Journal of Gastroenterology***

**Manuscript NO: 46715**

**Manuscript type: ORIGINAL ARTICLE**

***Observational Study***

**Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease**

Gong SS *et al*. Opportunistic infections in IBD patients

Shan-Shan Gong, Yi-Hong Fan, Qing-Qing Han, Bin Lv, Yi Xu

**Shan-Shan Gong, Yi-Hong Fan, Qing-Qing Han, Bin Lv, Yi Xu,** Department of Gastroenterology, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, Zhejiang Province, China

**ORCID number:** Shan-Shan Gong (0000-0001-5483-720X); Yi-Hong Fan (0000-0001-8217-9793); Qing-Qing Han (0000-0002-3155-3746); Bin Lv (0000-0002-6247-571X); Yi Xu (0000-0002-3265-9534).

**Author contributions:** Gong SS conducted clinical observation, analyzed the data, and wrote the paper; Fan YH designed the research and revised the paper; Han QQ collected the data; Xu Y and Lv B conducted literature search and provided valuable suggestions for this study; all authors have read and approved the final manuscript.

**Supported by** National Natural Science Foundation of China, No. 81473506; Natural Science Foundation of Zhejiang Province, No. LY16H290001 and No. LY17H290009; Project of Department of Construction of Zhejiang Province, No. WKJ-ZJ-1531; and Zhejiang TCM Science and Technology Project, No. 2016ZB047 and No. 2017ZA056.

**Institutional review board statement:** This study was approved by the institutional review board of First Affiliated Hospital of Zhejiang Chinese Medical University.

**Informed consent statement:** Informed consent was obtained from each patient.

**Conflict-of-interest statement:** The authors have declare no conflicts of interest.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The manuscript was prepared according to the STROBE checklist.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Corresponding author:** **Yi-Hong Fan,** **MD, PhD, Associate Professor, Chief Doctor,** Department of Gastroenterology, First Affiliated Hospital of Zhejiang Chinese Medical University, No. 54, Youdian Road, Shangcheng District, Hangzhou 310006, Zhejiang Province, China.yhfansjr@163.com

**Telephone:** +86-571-87608001

**Fax:** +86-571-87608001

**Received:** February 22, 2019

**Peer-review started:** February 22, 2019

**First decision:** March 5, 2019

**Revised:** March 11, 2019

**Accepted:** March 29, 2019

**Article in press:**

**Published online:**

**Abstract**

***BACKGROUND***

When opportunistic infections occur, patients with inflammatory bowel disease (IBD) commonly display a significantly increased rate of morbidity and mortality. With increasing use of immunosuppressive agents and biological agents, opportunistic infections are becoming a hot topic in the perspective of drug safety in IBD patients. Despite the well-established role of opportunistic infections in the prognosis of IBD patients, there are few epidemiological data investigating the incidence of opportunistic infections in IBD patients in China. Besides, the risk factors for opportunistic infection in Chinese IBD patients remain unclear.

***AIM***

To predict the incidence of opportunistic infections related to IBD in China, and explore the risk factors for opportunistic infections.

***METHODS***

A single-center, prospective study of IBD patients was conducted. The patients were followed for up to 12 mo to calculate the incidence of infections. For each infected IBD patient, two non-infected IBD patients were selected as controls. A conditional logistic regression analysis was used to assess associations between putative risk factors and opportunistic infections, which are represented as odds ratios (OR) and 95% confidence intervals (CIs).

***RESULTS***

Seventy (28.11%) out of 249 IBD patients developed opportunistic infections. *Clostridium difficile* infections and respiratory syncytial virus infections were found in 24 and 16 patients, respectively. In a univariate analysis, factors such as the severity of IBD, use of an immunosuppressant or immunosuppressants, high levels of fecal calprotectin, and C-reactive protein or erythrocyte sedimentation rate were individually related to a significantly increased risk of opportunistic infection. Multivariate analysis indicated that the use of any immunosuppressant yielded an OR of 3.247 (95%CI: 1.128-9.341), whereas the use of any two immunosuppressants yielded an OR of 6.457 (95%CI: 1.726-24.152) for opportunistic infection. Interestingly, when immunosuppressants were used in combination with infliximab (IFX) or 5-aminosalicylic acid, a significantly increased risk of opportunistic infection was also observed. The relative risk of opportunistic infection was greatest in IBD patients with severe disease activity (OR = 9.090; 95%CI: 1.532-53.941, relative to the remission stage). However, the use of IFX alone did not increase the risk of opportunistic infection.

***CONCLUSION***

Factors such as severe IBD, elevated levels of fecal calprotectin, and the use of immunosuppressive medications, especially when used in combination, are major risk factors for opportunistic infections in IBD patients. The use of IFX alone does not increase the risk of opportunistic infection.

**Key words:** Nested case-control study; Opportunistic infections; Inflammatory bowel disease

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** When opportunistic infections occur, patients with inflammatory bowel disease (IBD) commonly display a significantly increased rate of morbidity and mortality. With increasing use of immunosuppressive agents and biological agents, opportunistic infections are becoming a hot topic in the perspective of drug safety in IBD patients. Despite the well-established role of opportunistic infections in the prognosis of IBD patients, there are few epidemiological data investigating the incidence of opportunistic infections in IBD patients in China. Besides, the risk factors for opportunistic infections in Chinese IBD patients remain unclear.

Gong SS, Fan YH, Han QQ, Lv B, Xu Y. Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease. *World J Gastroenterol* 2019; In press

**INTRODUCTION**

Opportunistic infection refers to any infection caused by a weakened immune system and typically does not occur in people with normal immune function[1]. When they occur, patients presenting with opportunistic infections commonly display a significantly increased rate of morbidity and mortality. With increasing use of immunosuppressive agents and biological agents, opportunistic infections are becoming a hot topic in the perspective of drug safety in patients with inflammatory bowel disease (IBD). Studies have shown that opportunistic infections are closely related to the recurrence of IBD[2,3]. Severe opportunistic infection was observed in 3% of IBD patients, significantly increasing their mortality[4]. According to the consensus of The European Crohn’s and Colitis Organization on opportunistic infections in IBD, IBD patients taking glucocorticoids, immunomodulators, and biologic therapies are all at an increased risk of opportunistic infection. Malnutrition and old age are also key risk factors for opportunistic infections[5]. A multicenter prospective study conducted in Japan followed 570 patients with IBD for one year and observed 52 (9.1%) cases of opportunistic infection. Further analysis found that being over 50 years of age and the use of immunosuppressive agents are contributing risk factors for opportunistic infections in patients with IBD[6]. A study conducted by Tourner *et al*[7] also concluded that immunosuppressive medications and increased patient age are related with an increased risk of opportunistic infections in IBD patients. On the other hand, positive prevention, early diagnosis, and timely control of opportunistic infections are the current focuses for improving the prognosis of IBD patients.

 Despite the well-established role of opportunistic infections in the prognosis of IBD patients, there are few epidemiological data investigating the incidence of opportunistic infections in IBD patients in China. The level of fecal calprotectin (FC) is a commonly used diagnostic measure for patients with IBD as its levels generally increase in patients with IBD. It is generally accepted that FC levels are a stable and reliable measure of IBD severity with a high sensitivity and specificity. However, the relationship between FC levels and the incidence of opportunistic infections in IBD has never been studied.

Therefore, this study sought to investigate the relationship between IBD and opportunistic infections from a cohort of patients with IBD using a nested case-control method. Specifically, we sought to predict the incidence of opportunistic infections in patients with IBD in China, and determine the relationship between FC and opportunistic infection, with an aim to provide a scientific basis for the effective prevention and control of opportunistic infections in patients with IBD.

**MATERIALS AND METHODS**

***Research design and patient groups***

This study involving 301 IBD patients [139 with ulcerative colitis (UC) and 162 with Crohn’s disease (CD)] enrolled from January to December 2017. The probability of an opportunistic infection was calculated during a one-year follow-up period.Common opportunistic infections in patients with IBD include viral infections (herpes viruses, human papillomavirus, influenza virus, and JC virus), bacterial infections (tuberculosis, nocardia, *Clostridium difficile*, pneumococcus, legionella, and listeriosis), fungal infections (histoplasmosis, cryptococcosis, *Pneumocystis jirovecii* infection, aspergillosis, and candidiasis), and parasite infections (*Strongyloides stercoralis*)[8]. Patients were screened for opportunistic infection before enrollment to exclude those currently infected. Infection was based on laboratory results, in which viral IgM positivity and DNA copy were diagnosed as viral infection. The diagnosis of tuberculosis was based on the detection of *Tubercle bacillus*. *Clostridium difficile* was detected by PCR. Positive fecal cultures of mold and candida were diagnosed as fungal infections. Clinical visits were conducted once a month. Clinical follow-up and laboratory examinations [including routine blood examination, C-reactive protein (CRP), hepatic and renal function, FC, infection indicators, *etc.*] were conducted once a month. In addition, disease activity was assessed at each follow-up. Truelove and Witts disease severity classification criteria[9] and CD activity index (CDAI)[10] were used to evaluate the disease activity of patients with UC and CD, respectively. These diagnoses and disease activity index were admitted by the attending physician.

This study was approved by the ethics committee of First Affiliated Hospital of Zhejiang Chinese Medical University, and patients under the age of 16 were admitted to our study with the consent from their parents or guardians.

***Case-control study***

IBD patients with opportunistic infections were selected as the case group. For each case, two uninfected patients were chosen as controls and were matched according to age (at an interval of 10 years; ≤ 19, 20-29, 30-39,40-49, and ≥ 50 years).

***Data collection***

The demographic characteristics of patients were collected, including age, gender, course of the disease, current smoking habits, previous bowel surgery, comorbidity, disease activity, the type of IBD, and current medications. All patients were diagnosed with UC or CD based on the previously criteria[11].

***Statistical analysis***

Demographic characteristics were analyzed by the *t*-test. The univariate and multivariate analyses were performed with SPSS version 23 (SPSS, Tokyo, Japan).

**RESULTS**

***IBD patients’ demographic and clinical features***

A total of 301 IBD patients were enrolled in this study, 52 of whom were lost to follow-up. Of the remaining 249 patients, 119 had UC and 130 had CD. The patients’ ages ranged from 12 to 78 years (mean age, 45.24 years). During one year of follow-up, we found 70 IBD patients who developed an opportunistic infection (Table 1). The incidence of opportunistic infections was 28.11%. *Clostridium difficile* infection was found to be the most common opportunistic infection in patients with IBD (9.64%), followed by respiratory syncytial virus infection (6.43%). Fifteen (6.02%) and eleven (4.42%) patients were infected with Epstein-Barr virus and Fungal, respectively. One patient developed active tuberculosis.

 There were 70 patients in the case group, including 33 UC patients and 37 CD patients. In contrast, the control group consisted of 140 patients, including 66 UC patients and 74 CD patients. Selected demographic and clinical characteristics of cases and controls are provided in Table 2. There were no statistically significant differences between the two groups in age, gender, type of IBD, duration of IBD, duration of medication use, prior surgery or smoking history. The data of the two groups were well balanced and comparable.

***Severe disease activity is a risk factor for opportunistic infections in IBD patients***

Patients’ gender, age, type of IBD, duration of medication, course of the disease, history of prior surgery, and smoking habits were not related to increased risk of opportunistic infections, according to the univariate analysis. However, severe disease activity in IBD patients was related to an increased rate of opportunistic infections (*P* < 0.001, OR = 18.404; 95%CI: 3.833-88.375). Multivariate analysis also indicated that severe IBD was the greatest risk factor for opportunistic infections (*P* < 0.001, OR = 18.404; 95%CI: 3.833-88.375).

***Elevated level of FC is a risk factor for opportunistic infections in IBD patients***

In our study, FC higher than normal levels (>200 µg/g) was related to an increased risk of opportunistic infections both in our univariate analysis (*P* < 0.001, OR = 4.431; 95%CI: 2.265-8.667) and multivariate analysis (*P* = 0.023, OR = 2.467; 95%CI: 1.133-5.373).

***Immunosuppressive medications, especially when used in combination, are risk factors for opportunistic infections in IBD patients***

Compared with the use of 5-aminosalicylic acid (5-ASA), the use of infliximab (IFX) or 5-ASA+ IFX was not related to the incidence of opportunistic infections in our univariate analysis (Table 3) and multivariate analysis. On the contrary, the use of any immunosuppressant (steroids, azathioprine, tacrolimus, thalidomide, or methotrexate) was related to a significantly increased odd for opportunistic infection, compared with the use of 5-ASA both in univariate analysis (*P* < 0.047, OR = 2.668; 95%CI: 1.012-7.033) (Table 3) and multivariate analysis (*P* = 0.029, OR = 3.235; 95%CI: 1.125-9.306) (Figure 1). Especially when two or more immunosuppressants were used in combination, it represented the second largest risk factor for opportunistic infections in both univariate analysis (*P* < 0.001, OR = 10.375; 95%CI: 2.948-36.508) (Table 3) and multivariate analysis (*P* = 0.006, OR = 6.462; 95%CI: 1.727-24.172) (Figure 1). In addition, the use of 5-ASA and any immunosuppressant(s) or IFX with any immunosuppressant(s) was related to significantly increased infection rates both in univariate analysis (*P* < 0.01) (Table 3) and multivariate analysis (*P* < 0.05) (Figure 1).

***High levels of CRP and erythrocyte sedimentation rate (ESR) are not related to a significantly increased risk of opportunistic infection***

Our univariate analysis showed that high levels of CRP (OR = 3.98; 95%CI: 1.994-7.944) and ESR (OR = 3.744; 95%CI: 1.87-7.494) were related to an increased risk of opportunistic infections (Table 3). However, the results of multivariate analysis did not confirm this finding (Figure 1).

**DISCUSSION**

In our study, we prospectively predicted the occurrence of opportunistic infections in IBD patients. A total of 70 (28.11%) of the 249 patients developed opportunistic infections. Currently, there are few epidemiological data on the rate of opportunistic infection in IBD patients in China. In a study performed at Ruijin Hospital affiliated to Shanghai Jiao Tong University, of 130 patients with IBD, 12.3% developed CD infection[12]. In another study, positive serum IgG for cytomegalovirus (CMV) was found in 73% of UC patients in Wuhan, China and 89% of CD patients, and the rate in the healthy population was 50.69%[13]. Data from Peking Union Medical College Hospital indicated that the CMV infection rate in UC patients undergoing surgical operations was 46.2%[14], compared to 36.7% among refractory UC patients in Tianjin[15]. A multicenter prospective study conducted in Japan included 570 IBD patients who were followed for one year, and the authors observed 52 cases (9.1%) of opportunistic infection[7]. Separately, a national study in France found that the incidence of opportunistic infections in IBD patients was 7.9% after five years of follow-up[16]. The high incidence of opportunistic infection in IBD patients in China may be related to the level of economic development and the abuse of antibiotics. In most regions of China, expensive biological agents are not covered by medical insurance, which limits their extensive use in China. However, most immunosuppressants, such as steroids and azathioprine, are cheap and are accepted by the majority of IBD patients. China is known to be one of the countries with the worst rates of antibiotic abuse in the world. It is estimated that China produced 248000 tons of antibiotics in 2013[17], and the per capita consumption of antibiotics was 10 times that of the United States[18]. The direct consequence of abuse of antibiotics is widespread bacterial drug resistance, which results in an increased rate and severity of opportunistic infections.

 Infection with *Clostridium difficile*, an anaerobic, gram-positive bacillus, is the most common nosocomial infection which was most commonly observed in the IBD patients in our study (9.64%). IBD patients are at an increased risk for infection with *Clostridium difficile*[19-23]. Compared with those with IBD alone, patients with *Clostridium difficile* and IBD had longer hospital stay, requiring colon surgery intervention[24,25]. The use of antibiotics is closely related to *Clostridium difficile* associated diarrhea. Antimicrobials may disrupt the normal gastrointestinal flora, leading decreased colonization resistance and allowing toxigenic strains of *Clostridium difficile* to cause diseases. The abuse of antibiotics in China is serious. In addition, IBD patients are often treated with antibiotics for IBD deterioration or immunosuppressive complications, so *Clostridium difficile* infection can easily occur. *Clostridium difficile* is an increasing problem in immunocompromised patients, which can lead to higher rates of colectomy and mortality[26]. *Clostridium difficile* infection initiates with disruption of normal colonic microbiota, for which IBD patients are at high risk, conferring them an additional risk of *Clostridium difficile* infection[27,28]. In our pooled analysis, *Clostridium difficile* has the highest infection rate among opportunistic infections in IBD patients due to the extensive use of antibiotics and immunosuppressive agents.

 Our study found that disease severity was also a risk factor for opportunistic infections in IBD patients. Previously, the relationship between disease activity and the incidence of opportunistic infections was not clear. We speculate that when IBD patients progress to late-stage disease, a nonspecific inflammatory reaction is initiated in the gut mucosa, promoting pathogen invasion. The invasion of pathogens subsequently aggravates intestinal inflammation, creating a positive feedback loop. Furthermore, the increased energy consumption and low immunity state induced by inflammation diminish IBD patients’ ability to resist external pathogens, leading to further opportunistic infection.

 A reliable measure of long-term outcome is paramount in predicting the course of the disease, responsiveness to treatment, potential for complications, and need for hospitalization and/or surgery[29]. Many studies have shown that mucosal healing is the best predictor of positive long-term outcomes[30-33]. Endoscopy is currently regarded as the gold standard test for the assessment of mucosal healing[34]. However, its invasive nature and high cost make it an unfeasible modality for frequent monitoring. Calprotectin is an abundant calcium-binding protein, which is derived mainly from neutrophils and a lesser extent monocytes and reactive macrophages. FC is a sensitive marker of intestinal inflammation in IBD, as its concentration reflects the migration of neutrophils into the intestinal cavity[35]. Thus, FC has emerged as a novel diagnostic tool to detect and monitor intestinal inflammation and reflect disease activity in IBD. Measurements for FC are simple, rapid, specific, sensitive, and inexpensive compared to its counterparts[36,37]. Along with CRP, ESR, and FC, our study discovered that elevated FC was a risk factor for opportunistic infections in IBD patients. One explanation for this finding may be that the level of FC serves as an indicator for intestinal inflammation and therefore, disease activity. This makes FC level a more sensitive and specific marker than CRP and ESR. When the level of FC in IBD patients is elevated, it suggests that intestinal inflammation has occurred and the disease is in an active stage, conferring the patient to opportunistic infections.

 In our study, immunosuppressive agents included methotrexate, 6-mercaptopurine, azathioprine, thalidomide, tacrolimus and steroids. From this study, we have found that the use of immunosuppressive medications alone increased the risk of an opportunistic infection about 3.247-fold. When any two immunosuppressive medications were used in conjunction, the risk was increased greatly to about 6.457-fold. This result from our study is consistent with recent results in the literature[7,8,38,39]. Additionally, it was determined that when immunosuppressive medications were combined with 5-ASA or IFX, the risk of opportunistic infection was increased greatly to about 4 to 5 folds. This conclusion is consistent with the findings reported by Tourner *et al*[7], Lawrance *et al*[40], and Kirchgesner *et al*[16].

 The relationship between biologics and opportunistic infections has not been clearly established. Some studies[41-44] indicated that biologics increase the incidence of opportunistic infections, while others do not support this conclusion[45,46]. In our study, we found no association between the use of IFX alone and the increased risk of opportunistic infections. One possible explanation is that IFX may not cause opportunistic infections within the one-year period of the study (shorter than the previous five-year period)[7].

 Despite the important findings, this study had several limitations. First, the sample size of our study was small. A larger sample size would have allowed for more accurate estimation of the incidence of opportunistic infections and increase in reliability of risk factors in Chinese IBD patients. Second, our study was a single-center clinical study, which cannot represent the situation of IBD patients in China as a whole.

 In conclusion, severe disease activity, elevated levels of FC, and immunosuppressive medications, especially when used in combination, are risk factors for opportunistic infections in IBD patients. The use of IFX alone has nothing to do with opportunistic infections. With the increasing use of immunosuppressants in IBD and the advocacy of combination therapy, patients and physicians need to pay attention to and prevent opportunistic infections. As the genetic background, living environment, lifestyle, and diet of IBD patients in China are different from those in Western countries, our study of opportunistic infection could provide vital information for clinicians and IBD patients in China and other countries.

**Article Highlights**

***Research background***

Opportunistic infection refers to any infection caused by a weakened immune system and typically does not occur in people with normal immune function. When they occur, patients presenting with opportunistic infections commonly display a significantly increased rate of morbidity and mortality. A number of studies have been conducted in Western countries and Japan to investigate the incidence of and risk factors for opportunistic infection in inflammatory bowel disease (IBD) patients. Currently, there are few epidemiological data on the rate of opportunistic infection in IBD patients in China. The risk factors for opportunistic infection in Chinese IBD patients remain unclear.

***Research motivation***

The main topics in our study are to predict the incidence of opportunistic infections related to IBD in China, and explore the risk factors for opportunistic infections. The key problems to be solved is to ensure compliance of enrolled IBD patients. The significance of solving these problems for future research in this field is to more accurately predict the incidence of and risk factors for opportunistic infections.

***Research objectives***

The main objectives in our study were to predict the incidence of opportunistic infections related to IBD in China, and explore the risk factors for opportunistic infections. The realized objectives include that the incidence of opportunistic infection in IBD patients in China is higher than that in Western countries and factors such as severe IBD, elevated levels of fecal calprotectin, and the use of immunosuppressive medications, especially when used in combination, are major risk factors for opportunistic infections in IBD patients, according to our single-center study. The significance of realizing these objectives for future research in this field is to alert patients and physicians to pay attention to and prevent opportunistic infections. Meanwhile, our study can provide important information for clinicians and IBD patients in China and other countries.

***Research methods***

The research design that was adopted to realize the objectives is observational study and nested case-control study. Observational study is to observe and record the characteristics of research objects in a natural state, and describe and compare the results. In our study, the patients were followed for up to 12 mo to identify the incidence of infections. In nested case-control studies, cases and controls come from the same cohort, so the selection bias in effect estimation is reduced and comparability is good. For each infected IBD patient, two non-infected IBD patients were selected as controls in our study.

***Research results***

Our study found that the incidence of opportunistic infection in IBD patients in China is higher than that in Western countries and factors such as severe IBD, elevated levels of fecal calprotectin, and the use of immunosuppressive medications, especially when used in combination, are major risk factors for opportunistic infections in IBD patients. Meanwhile, the use of infliximab alone does not increase the risk of opportunistic infection. Our findings remind patients and physicians to pay attention to and prevent opportunistic infections. As the genetic background, living environment, lifestyle, and diet of IBD patients in China are different from patients in Western countries, our study of opportunistic infection could provide important information for clinicians and IBD patients in China and other countries. The following problems remain to be solved: (1) Our study was a single-center clinical study, which cannot represent the situation of IBD patients in China as a whole; and (2) the sample size of this study for both ulcerative colitis and Crohn’s disease patients was small. A larger sample size would have allowed for more precise estimation of the incidence of opportunistic infections and increase in reliability of risk factors in Chinese IBD patients.

***Research conclusions***

The new findings of this study are that the incidence of opportunistic infection in IBD patients in China is higher than that in Western countries, according to our single-center study, and factors such as severe IBD, elevated levels of fecal calprotectin, and the use of immunosuppressive medications, especially when used in combination, are major risk factors for opportunistic infections in IBD patients. Meanwhile, the use of infliximab alone does not increase the risk of opportunistic infection. The original insights into the current knowledge that this study offered is when opportunistic infection occurs, patients commonly display a significantly increased rate of morbidity and mortality. Therefore, prevention and identification of opportunistic infections are critical. The implications of this study for clinical practice in the future is patients and physicians need to pay attention to and prevent opportunistic infections.

***Research perspectives***

From this study, we can conclude that the incidence of opportunistic infection in IBD patients in China is higher than that in Western countries, and doctors should pay attention to and prevent the incidence of opportunistic infections. The future research direction is to conduct a multi-center study to evaluate the incidence of opportunistic infection in Chinese IBD patients, and more accurately screen out the risk factors leading to the occurrence of opportunistic infection in Chinese IBD patients, so as to effectively prevent the occurrence of opportunistic infection.

**REFERENCES**

1 **Bryant PA**, Baddley JW. Opportunistic Infections in Biological Therapy, Risk and Prevention. *Rheum Dis Clin North Am* 2017; **43**: 27-41 [PMID: 27890172 DOI: 10.1016/j.rdc.2016.09.005]

2 **Mylonaki M**, Langmead L, Pantes A, Johnson F, Rampton DS. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. *Eur J Gastroenterol Hepatol* 2004; **16**: 775-778 [PMID: 15256979]

3 **Axelrad JE**, Joelson A, Nobel YR, Lawlor G, Green PHR, Lichtiger S, Lebwohl B. Enteric Infection in Relapse of Inflammatory Bowel Disease: The Utility of Stool Microbial PCR Testing. *Inflamm Bowel Dis* 2017; **23**: 1034-1039 [PMID: 28511200 DOI: 10.1097/MIB.0000000000001097]

4 **Siegel CA**. Review article: explaining risks of inflammatory bowel disease therapy to patients. *Aliment Pharmacol Ther* 2011; **33**: 23-32 [PMID: 21083583 DOI: 10.1111/j.1365-2036.2010.04489.x]

5 **Rahier JF**, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, Macmahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF; European Crohn's and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. *J Crohns Colitis* 2014; **8**: 443-468 [PMID: 24613021 DOI: 10.1016/j.crohns.2013.12.013]

6 **Naganuma M**, Kunisaki R, Yoshimura N, Takeuchi Y, Watanabe M. A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease. *J Gastroenterol* 2013; **48**: 595-600 [PMID: 23053426 DOI: 10.1007/s00535-012-0686-9]

7 **Toruner M**, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ. Risk factors for opportunistic infections in patients with inflammatory bowel disease. *Gastroenterology* 2008; **134**: 929-936 [PMID: 18294633 DOI: 10.1053/j.gastro.2008.01.012]

8 **Dave M**, Purohit T, Razonable R, Loftus EV Jr. Opportunistic infections due to inflammatory bowel disease therapy. *Inflamm Bowel Dis* 2014; **20**: 196-212 [PMID: 24051931 DOI: 10.1097/MIB.0b013e3182a827d2]

9 **Truelove SC**, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. *Br Med J* 1955; **2**: 1041-1048 [PMID: 13260656]

10 **Best WR**, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. *Gastroenterology* 1976; **70**: 439-444 [PMID: 1248701]

11 **Inflammatory enterology group**, Chinese society of gastroenterology. Consensus on diagnosis and treatment of inflammatory bowel disease (Beijing, 2018). *Zhongguo Xiaohua Waike Zazhi* 2018; **38**: 292-311 [DOI: 10.3760/cma.j.issn.02541432.2018.05.002]

12 **Liu JJ**, Yuan YZ. A preliminary study on the relationship between clostridium difficile and inflammatory bowel disease. *Zhongguo Xiaohua Waike Zazhi* 2012; **32**: 245-248 [DOI: 10.3760/cma.j.issn.0254-1432.2012.04.007]

13 **Yi F**, Zhao J, Luckheeram RV, Lei Y, Wang C, Huang S, Song L, Wang W, Xia B. The prevalence and risk factors of cytomegalovirus infection in inflammatory bowel disease in Wuhan, Central China. *Virol J* 2013; **10**: 43 [PMID: 23374225 DOI: 10.1186/1743-422X-10-43]

14 **Li J**, Lyu H, Yang H, Li Y, Tan B, Wei MM, Sun XY, Li JN, Wu B, Qian JM. Preoperative Corticosteroid Usage and Hypoalbuminemia Increase Occurrence of Short-term Postoperative Complications in Chinese Patients with Ulcerative Colitis. *Chin Med J* (Engl) 2016; **129**: 435-441 [PMID: 26879017 DOI: 10.4103/0366-6999.176072]

15 **Li TT**, Lv ZS, Wang BM, Zhang J. Relationship between refractory ulcerative colitis and eytomegalovirus infection. *Shi Jie Hua Ren Xiao Hua Za Zhi* 2014; **18**: 1174-1177 [DOI: 10.3969/j.issn.1009-3079.2010.11.017]

16 **Kirchgesner J**, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. *Gastroenterology* 2018; **155**: 337-346.e10 [PMID: 29655835 DOI: 10.1053/j.gastro.2018.04.012]

17 **Zhang QQ**, Ying GG, Pan CG, Liu YS, Zhao JL. Comprehensive evaluation of antibiotics emission and fate in the river basins of China: source analysis, multimedia modeling, and linkage to bacterial resistance. *Environ Sci Technol* 2015; **49**: 6772-6782 [PMID: 25961663 DOI: 10.1021/acs.est.5b00729]

18 **Wang S**, Hu YJ, Little P, Wang Y, Chang Q, Zhou X, Moore M, Harwell JI. The impact of the national action plan on the epidemiology of antibiotic resistance among 352,238 isolates in a teaching hospital in China from 2015 to 2018. *Antimicrob Resist Infect Control* 2019; **8**: 22 [PMID: 30728954 DOI: 10.1186/s13756-019-0473-y]

19 **Razik R**, Rumman A, Bahreini Z, McGeer A, Nguyen GC. Recurrence of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: The RECIDIVISM Study. *Am J Gastroenterol* 2016; **111**: 1141-1146 [PMID: 27215924 DOI: 10.1038/ajg.2016.187]

20 **Leffler DA**, Lamont JT. Clostridium difficile Infection. *N Engl J Med* 2015; **373**: 287-288 [PMID: 26176396 DOI: 10.1056/NEJMc1506004]

21 **Issa M**, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. *Inflamm Bowel Dis* 2008; **14**: 1432-1442 [PMID: 18484669 DOI: 10.1002/ibd.20500]

22 **Ananthakrishnan AN**, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. *Gut* 2008; **57**: 205-210 [PMID: 17905821 DOI: 10.1136/gut.2007.128231]

23 **Nguyen GC**, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. *Am J Gastroenterol* 2008; **103**: 1443-1450 [PMID: 18513271 DOI: 10.1111/j.1572-0241.2007.01780.x]

24 **Goodhand JR**, Alazawi W, Rampton DS. Systematic review: Clostridium difficile and inflammatory bowel disease. *Aliment Pharmacol Ther* 2011; **33**: 428-441 [PMID: 21198703 DOI: 10.1111/j.1365-2036.2010.04548.x]

25 **Jodorkovsky D**, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. *Dig Dis Sci* 2010; **55**: 415-420 [PMID: 19255850 DOI: 10.1007/s10620-009-0749-9]

26 **Binion DG**. Strategies for management of Clostridium difficile infection in immunosuppressed patients. *Gastroenterol Hepatol* (NY) 2011; **7**: 750-752 [PMID: 22298971]

27 **Monaghan TM**, Cockayne A, Mahida YR. Pathogenesis of Clostridium difficile Infection and Its Potential Role in Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2015; **21**: 1957-1966 [PMID: 26199993 DOI: 10.1097/MIB.0000000000000461]

28 **Kostic AD**, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. *Gastroenterology* 2014; **146**: 1489-1499 [PMID: 24560869 DOI: 10.1053/j.gastro.2014.02.009]

29 **Simon EG**, Wardle R, Thi AA, Eldridge J, Samuel S, Moran GW. Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn's disease? - a systematic review. *Intest Res* 2019 [PMID: 30704158 DOI: 10.5217/ir.2018.00114]

30 **Frøslie KF**, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. *Gastroenterology* 2007; **133**: 412-422 [PMID: 17681162 DOI: 10.1053/j.gastro.2007.05.051]

31 **Schnitzler F**, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. *Inflamm Bowel Dis* 2009; **15**: 1295-1301 [PMID: 19340881 DOI: 10.1002/ibd.20927]

32 **Colombel JF**, Rutgeerts PJ, Sandborn WJ, Yang M, Camez A, Pollack PF, Thakkar RB, Robinson AM, Chen N, Mulani PM, Chao J. Adalimumab induces deep remission in patients with Crohn's disease. *Clin Gastroenterol Hepatol* 2014; **12**: 414-422.e5 [PMID: 23856361 DOI: 10.1016/j.cgh.2013.06.019]

33 **Baert F**, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S, D'Haens G; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. *Gastroenterology* 2010; **138**: 463-468; quiz e10-1 [PMID: 19818785 DOI: 10.1053/j.gastro.2009.09.056]

34 **Annese V**, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Götz M, Katsanos KH, Kießlich R, Ordás I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R; European Crohn's and Colitis Organisation. European evidence based consensus for endoscopy in inflammatory bowel disease. *J Crohns Colitis* 2013; **7**: 982-1018 [PMID: 24184171 DOI: 10.1016/j.crohns.2013.09.016]

35 **Bjerke K**, Halstensen TS, Jahnsen F, Pulford K, Brandtzaeg P. Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. *Gut* 1993; **34**: 1357-1363 [PMID: 8244101]

36 **Ayling RM**, Kok K. Fecal Calprotectin. *Adv Clin Chem* 2018; **87**: 161-190 [PMID: 30342711 DOI: 10.1016/bs.acc.2018.07.005]

37 **Fadeeva NA**, Korneeva IA, Knyazev OV, Parfenov AI. Biomarkers of inflammatory bowel disease activity. *Ter Arkh* 2018; **90**: 107-111 [PMID: 30701842 DOI: 10.26442/00403660.2018.12.000018]

38 **Zabana Y**, Rodríguez L, Lobatón T, Gordillo J, Montserrat A, Mena R, Beltrán B, Dotti M, Benitez O, Guardiola J, Domènech E, Garcia-Planella E, Calvet X, Piqueras M, Aceituno M, Fernández-Bañares F, Esteve M. Relevant infections in inflammatory bowel disease, their relationship with immunosuppressive therapy and their effects on disease mortality. *J Crohns Colitis* 2019 [PMID: 30668662 DOI: 10.1093/ecco-jcc/jjz013]

39 **Hasani Z**, Aghdaei HA, Balaii H, Azimirad M, Mirsamadi ES, Mirjalali H, Zali MR. The first study on opportunistic intestinal microsporidiosis in IBD patients receiving immunosuppressive medications in Iran. *Epidemiol Infect* 2017; **145**: 2095-2099 [PMID: 28502260 DOI: 10.1017/S0950268817000954]

40 **Lawrance IC**, Radford-Smith GL, Bampton PA, Andrews JM, Tan PK, Croft A, Gearry RB, Florin TH. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience. *J Gastroenterol Hepatol* 2010; **25**: 1732-1738 [PMID: 21039834 DOI: 10.1111/j.1440-1746.2010.06407.x]

41 **Bonovas S**, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, Danese S. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. *Clin Gastroenterol Hepatol* 2016; **14**: 1385-1397.e10 [PMID: 27189910 DOI: 10.1016/j.cgh.2016.04.039]

42 **Souto A**, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. *Rheumatology* (Oxford) 2014; **53**: 1872-1885 [PMID: 24821849 DOI: 10.1093/rheumatology/keu172]

43 **Ford AC**, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. *Am J Gastroenterol* 2013; **108**: 1268-1276 [PMID: 23649185 DOI: 10.1038/ajg.2013.138]

44 **Borman ZA**, Côté-Daigneault J, Colombel JF. The risk for opportunistic infections in inflammatory bowel disease with biologics: an update. *Expert Rev Gastroenterol Hepatol* 2018; **12**: 1101-1108 [PMID: 30277409 DOI: 10.1080/17474124.2018.1530983]

45 **Genevay S**, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. *Arthritis Rheum* 2007; **57**: 679-685 [PMID: 17471545 DOI: 10.1002/art.22688]

46 **Schneeweiss S**, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. *Arthritis Rheum* 2007; **56**: 1754-1764 [PMID: 17530704 DOI: 10.1002/art.22600]

**P-Reviewer:** Day AS, Perse M, Seicean A

**S-Editor:** Ma RY **L-Editor:** Wang TQ **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

**Table 1 Opportunistic infections in inflammatory bowel disease patients evaluated between January 1, 2017 and December 31, 2018**

|  |  |  |
| --- | --- | --- |
| **Organism** | **Number of UC patients** | **Number of CD patients** |
| Mycobacterium tuberculosis | 1 | 0 |
| Epstein-Barr virus | 10 | 5 |
| Cytomegalovirus | 3 | 1 |
| Hepatotropic virus | 0 | 1 |
| Clostridium difficile | 11 | 13 |
| Adenovirus | 0 | 3 |
| Syncytial virus | 5 | 11 |
| Coxsaccie virus | 1 | 2 |
| Herpes simplex virus | 3 | 2 |
| Herpes zoster | 0 | 1 |
| Mold | 6 | 3 |
| Candida albicans | 2 | 0 |
| Streptococcus | 1 | 2 |

Three patients were co-infected with Epstein-Barr virus (EBV) and respiratory syncytial virus (S virus). Two patients were co-infected with EBV and mold. One patient was co-infected with EBV and *Clostridium difficile* (CDI). One patient was co-infected with EBV and cytomegalovirus (CMV). One patient was co-infected with EBV and herpes simplex virus (HSV). One patient was co-infected with EBV, S virus, and Coxsaccie virus (C virus). One patient was co-infected with mold and CDI. One patient was co-infected with adenovirus and S virus. One patient was co-infected with adenovirus and C virus. One patient was co-infected with CDI and C virus. One patient was co-infected with CDI and S virus. One patient was co-infected with CDI, mold, and Streptococcus. UC: Ulcerative colitis; CD: Crohn’s disease.

**Table 2 Demographic and clinical features of inflammatory bowel disease patients with (cases) and without (controls) opportunistic infection**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Cases (*n* = 70)** | **Controls (*n* = 140)** | ***P*-value** |
| Median age | 45.67 ± 15.79 | 44.13 ± 14.21 | 0.45 |
| Gender |  |  | 0.11 |
| Male | 39 | 89 |  |
| Female | 31 | 51 |
| Type of IBD |  |  | 0.82 |
| UC | 33 | 66 |  |
| Proctitis | 4 | 24 |
| Left-sided | 7 | 15 |
| Extensive | 22 | 27 |
| CD | 37 | 74 |
| Ileitis (L1) | 9 | 23 |
| Colitis (L2) | 6 | 3 |
| Ileocolitis (L3) | 17 | 26 |
| Upper gastrointestinal tract (L4) | 1 | 4 |
| L1 + L4 | 0 | 5 |
| L2 + L4 | 0 | 2 |
| L3 + L4 | 4 | 11 |
| Duration of IBD (yr) | 6.42 ± 6.01 | 5.12 ± 4.04 | 0.28 |
| Duration of medication (yr) | 2.73 ± 2.02 | 2.54 ± 2.11 | 0.71 |
| Prior surgery | 25 | 41 | 0.31 |
| Smoking | 2 | 13 | 0.11 |

L1; Ileitis; L2: Colitis; L3: Ileocolitis; L4: Upper gastrointestinal tract; IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn’s disease.

**Table 3 Risk factors for opportunistic infection in inflammatory bowel disease patients (univariate analysis)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Cases (*n* = 70)** | **Controls (*n* = 140)** | ***P*-value** | **Odds ratio** | **95%CI** |
| Disease activity |  |  |  |  |  |
| Remission | 25 | 85 | Reference |
| Mildly active | 20 | 40 | 0.145 | 1.673 | 0.837-3.345 |
| Moderate  | 14 | 13 | 0.004 | 3.604 | 1.505-8.626 |
| Severe  | 11 | 2 | <0.001 | 18.404 | 3.833-88.375 |
| Treatment |  |  |  |  |  |
| 5-ASA | 20 | 83 | Reference |
| Any IS | 8 | 12 | 0.047 | 2.668 | 1.012-7.033 |
| Any two IS | 10 | 4 | <0.001 | 10.375 | 2.948-36.508 |
| Infliximab | 13 | 24 | 0.109 | 1.992 | 0.857-4.632 |
| 5-ASA + any IS | 11 | 9 | 0.002 | 5.072 | 1.853-13.887 |
| Infliximab + any IS | 9 | 7 | 0.003 | 5.336 | 1.773-16.058 |
| FC > ULN | 57 | 69 | <0.001 | 4.431 | 2.265-8.667 |
| CRP > ULN | 26 | 18 | <0.001 | 3.98 | 1.994-7.944 |
| ESR > ULN | 25 | 18 | <0.001 | 3.744 | 1.87-7.494 |

5-ASA: 5-aminosalicylic acid; IS: Immunosuppressant (steroids, thiopurine, thalidomide, tacrolimus, or methotrexate);FC: Fecal calprotectin; CRP:C-reaction protein; ESR: Erythrocyte sedimentation rate;ULN: Upper limit of normal; CI: Confidence interval.



**Figure 1 Risk factors for opportunistic infection in inflammatory bowel disease patients (multivariate analysis).** 5-ASA: 5-aminosalicylic acid; IS: Immunosuppressant (steroids, thiopurine, thalidomide, tacrolimus, or methotrexate); FC: Fecal calprotectin; CRP: C-reaction protein; ESR: Erythrocyte sedimentation rate; ULN: Upper limit of normal; CI: Confidence interval. *P-*values and 95% confidence intervals (CIs) for mild, moderate, and severe disease were compared with remission. *P*-values and 95%CIs for any immunosuppressant (IS), any two IS, infliximab, 5-aminosalicylic acid (5-ASA) + any IS, and infliximab + any IS were compared with 5-ASA.